About Matt Eagleton, MD

Matthew Eagleton, MD, is an accomplished vascular surgeon who treats all aspects of peripheral vascular disease. He is an international expert on the treatment of complex aortic disease with endovascular therapy. He is the chief of the Division of Vascular and Endovascular Surgery and co-director of the Fireman Vascular Center at Massachusetts General Hospital, and leads a multidisciplinary team that manages vascular disease. In addition, he is co-director of the Mass General Thoracic Aortic Center.

Dr. Eagleton received his medical degree in 1994 and completed his general surgery residency in 2000, both at the University of Rochester. In 2002, he completed specialty training in vascular surgery at the University of Michigan and obtained advanced training in endovascular procedures at the Cleveland Clinic. Prior to his current role at Mass General, Dr. Eagleton was a professor of surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and vice-chairman of the Department of Vascular Surgery and director of vascular surgery at the Cleveland Clinic Aortic Center. In addition, he held the role of program director, overseeing the educational program for the Cleveland Clinic’s Integrated Residency (0+5), Independent Fellowship (5+2) training programs in vascular surgery and their Endovascular Mini-fellowship and Aortic Fellowship.

Dr. Eagleton has served in a variety of national organizations including the Vascular and Endovascular Surgical Society and the Society for Vascular Surgery. He just completed a four-year term as chair of the program committee for the Vascular Annual Meeting of the Society for Vascular Surgery.

Dr. Eagleton conducts clinical research evaluating the use of fenestrated and branched aortic endograft technology to treat complex aortic disease through a physician-sponsored investigational device exemption trial. In addition, he has been involved in numerous endograft clinical trials serving as an investigator, national principal investigator and advisor. He collaborates with a team of physicians, both locally and internationally, to better understand how to provide safer, more durable treatment options to patients with life-threatening aortic disease. Dr. Eagleton serves as director of the scientific advisory board for Centerline Biomedical and he serves on the scientific advisory board for ViTAAA and Nectero, which are biomedical research companies aimed at developing improved treatment options for patients with vascular disease.

In his personal life, Dr. Eagleton enjoys cooking with sous vide and running. He is also a member of the Sons of the American Revolution.

Clinical Interests:

Treats:

Locations

Mass General Vascular Center: Vascular and Endovascular Surgery
55 Fruit St..
Boston, MA 02114
Phone: 617-726-8278

Medical Education

  • MD, University of Rochester School of Medicine
  • Fellowship, University of Michigan

American Board Certifications

  • General Surgery, American Board of Surgery
  • Vascular Surgery, American Board of Surgery

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Eagleton has harbored a passion for aortic disease throughout his career. Currently he conducts clinical research evaluating the use of fenestrated and branched aortic endograft technology to treat complex aortic disease through a physician-sponsored investigational device exemption trial. In addition, he has been involved in numerous endograft clinical trials serving as an investigator, national principal investigator, and advisor. He collaborates with a team of physicians both locally and across the globe in helping to better understand how to provide safer, more durable treatment options to patients with life-threatening aortic disease. Dr. Eagleton serves on the scientific advisory board for Aortica and is the chair of the scientific advisory board for Centerline Biomedical, two biomedical research companies aimed at developing improved treatment options for patients with vascular disease.

Publications

  • Select Publications:

    • Beach JM, Rajeswaran J, Parodi F, Kurmamochi Y, Brier C, Blackstone E, Eagleton MJ. Survival affects decision making for fenestrated and branched endovascular aortic repair. J Vasc Surg, 2017. PMID 28967527
    • Farivar BS, Abbasi MN, Dias AP, Kuramochi Y, Brier CS, Parodi FE, Eagleton MJ. Durability of iliac artery preservation associated with endovascular repair of infrarenal aortoiliac aneurysms. J Vasc Surg 207; 66: 1028-36. PMID: 28502545
    • Beach JM, Kuramochi Y, Brier C, Roselli EE, Eagleton MJ. Durable outcomes of thoracic endovascular repair with Zenith TX1 and TX2 devices. J Vasc Surg 2017; 65: 1287-96. PMID: 28216363
    • Eagleton MJ, Follansbee MR, Wolski K, and Kuramochi Y. Fenestrated and branched endovascular aneurysm repair outcomes for type II and III thoracoabdominal aortic aneurysms. J Vasc Surg 2016. 63: 930-42. PMID 26792544
    • Sylvan J, Brier C, Wolski K, Yanof J, Goel V, Kuramochi Y, and Eagleton MJ. Impact of alterations in target vessel curvature on branch durability following endovascular repair of thoracoabdominal aortic aneurysms. J Vasc Surg, 2016. 63: 634-41. PMID 26620715
    • O’Callaghan A, Mastracci TM, Eagleton MJ. Staged endovascular repair of thoracoabdominal aortic aneurysms limits incidence and severity of spinal cord ischemia. J Vasc Surg 2015; 61: 347-54. .

Reviews: Comments and Ratings